Nutraceuticals silybin B, resveratrol, and epigallocatechin-3 gallate-bind to cardiac muscle troponin to restore the loss of lusitropy caused by cardiomyopathy mutations in vitro, in vivo, and in silico
The uncoupling phenomenon caused by cardiomyopathy-related mutations and the ability of small molecules to restore coupling <i>in vitro</i> and lusitropy in myocytes is observed at the cellular, molecular and atomistic levels therefore, restoring lusitropy is a suitable target for treatment. Further research on compounds that restore lusitropy is thus indicated as treatments for genetic cardiomyopathies. Further molecular dynamics simulations could define the specific properties needed for recoupling and allow for the prediction and design of potential new drugs.
Authors
- Andrew E. Messer
- Vladimı́r Křen (ORCID: https://orcid.org/0000-0002-1091-4020)
- Zeyu Yang (ORCID: https://orcid.org/0000-0002-2957-8063)
- Ian R. Gould (ORCID: https://orcid.org/0000-0003-3559-0234)
- Alexander J. Sparrow (ORCID: https://orcid.org/0000-0002-3354-3314)
- Charles Redwood (ORCID: https://orcid.org/0000-0002-8673-7542)
- Steven B. Marston (ORCID: https://orcid.org/0000-0001-6054-6070)
- Alice Sheehan
- Sharmane Tsui
Institutions
- Czech Academy of Sciences (CZ)
- British Heart Foundation (GB)
- University of Oxford (GB)
- Czech Academy of Sciences, Institute of Microbiology (CZ)
- Imperial College London (GB)
Publication Details
- Journal
- Frontiers in Physiology
- Published
- 2024-12-13
- DOI
- https://doi.org/10.3389/fphys.2024.1489439
- Citations
- 3
- Primary Topic
- Ion channel regulation and function
- Type
- article
- Field-Weighted Citation Impact
- 0.70
Funders
- British Heart Foundation